Auswahl relevanter Publikationen

Leucht S, Wahlbeck K, Hamann J, Kissling W (2003): New generation antipsychotics versus low-potency conventional antipsychotics. A systematic review and meta-analysis. Lancet 361:1581-1589.

Leucht S, Pitschel-Walz G, Engel R, Kissling W (2002) Amisulpride – an unusual atypical antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159:180-190

Leucht S, Barnes TRE, Kissling W, Engel R, Correll C, Kane J (2003). Relapse prevention in schizophrenia with new generation antipsychotics. A systematic review and meta-analysis of randomised controlled trials. Am J Psychiatry 160:1209-1222.

Correll CU, Leucht S, Kane JM (2004) Reduced Risk for Tardive Dyskinesia Associated with Second Generation Antipsychotics: A Systematic Review of One-Year Studies. American Journal of Psychiatry 161:414-425.

Leucht S, McGrath J, White P, Kissling w (2002) Carbamazepine for schizophrenia – how good is the evidence J Clin Psychiatry 63:218-224

Leucht S, Kissling W, McGrath J (2004) Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomised controlled trials. Journal of Clinical Psychiatry 65:177-186

Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K,  Ioannidis JPA; for the EU-PSI project (2005). Evolution over time of evidence from randomised trials on mental health interventions. J Cin Epidemiol 57:1124-1130

Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak P, Kissling W (2001) Doxepin plasma concentrations: Is there really a therapeutic range? J Clin Psychopharmacol 21: 432-439

Leucht S, Abraham D, Kissling W, 1999. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35:51-68.

Basan A, Kissling W, Leucht S (2004) Valproate as an adjunct to antipsychotics for schizophrenia: A systematic review of randomized trials. Schizophrenia Research 70(1):33-37

Leucht S, Wagenpfeil S, Hamann J, Kissling W (2004) Amisulpride is an “atypical” antipsychotic associated with low weight gain. Psychopharmacology 173:112-115.

Wahlbeck K, Tuunainen A, Ahokas A, Leucht S (2001) Drop-out rates in randomised antipsychotic drug trials. Psychopharmacology 155: 230-233

Hamann J, Leucht S, Kissling W (2003) Are the second generation antipsychotics cost effective? Pharmacopsychiatry 36:18-26.

Pitschel-Walz G, Leucht S, Bäuml J, Kissling W, Engel RR (2001) The effect of family intervention in schizophrenia – a meta-analysis. Schizophrenia Bulletin 27 (1):73-92.

Heres S, Wagenpfeil S, Hamann J, Kissling W, Leucht S.  Language bias in neuroscience - is the Tower of Babel located in Germany? Eur Psychiatry 2004;19(4):230-2

Röder C, Schäfer M, Leucht S (2004). Meta-Analyse zu Wirksamkeit und Verträglichkeit der Behandlung der leichten und mittelschweren Depression mit Johanniskraut. Fortschr Neurol Psychiatr: 330-343

Rummel C, Hamann J, Kissling W, Leucht S. New generation antipsychotics for first episode schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.

Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database Syst Rev. 2000;(2):CD001258.

Leucht S, McGrath J, Kissling W. Lithium for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.

Leucht S, Hartung B. Perazine for schizophrenia (Cochrane Review). Cochrane Database Syst Rev. 2002;(1):CD002832.

Leucht S, Hartung B. Benperidol for schizophrenia (Cochrane Review). Cochrane Database Syst Rev. 2002;(2):CD002832.

Basan A, Kissling W, Leucht S (2004) Valproate for schizophrenia (Cochrane Review). The Cochrane Library, issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.

Hartung B, Wada M, Laux G, Leucht S (2005) Perphenazine for schizophrenia (Cochrane Review). The Cochrane Library, issue 1, 2005.

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR (2005a): Clinical implications of Brief Psychiatric Rating Scale scores. Br.J.Psychiatry 187: 366-371.        

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR (2005) What does the PANSS mean? Schizophrenia Research; 79:231-238

Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005) Early onset of antipsychotic drug action. A hypothesis tested, confirmed and extended. Biological Psychiatry, 57:1543-1549.

Stiegler M, Rummel C, Wahlbeck K, Kissling W, Leucht S (2005) European psychiatric treatment guidelines. Is the glass half full or half empty. European Psychiatry, 20:554-558.

Rummel C, Kissling W, Leucht S (2005) Antidepressants as add-on therapy to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizo Res 80:85-97

Heres S, Davis JM, Maino K, Jetzinger E, Kissling W, Leucht S (2006) Why olanzapine beats risperidone, risperidone beats quetiapine and quetiapine beats olanzapine again. An exploratory analysis of head-to-head comparisons of second generation antipsychotics. Am J Psych 2006;163:18-194